Introduction
The tumor cells of highly curable malignancies such as some leukemias, testicular and Wilms cancers, easily undergo apoptosis (cell death mediated by caspase activation), fueling the notion that apoptosis is the goal of chemotherapy. [1] [2] [3] [4] [5] [6] [7] [8] Caspases, a family of the cysteine proteases, cleave the cellular proteins resulting in rapid cell death often accompanied by the nuclear and DNA fragmentation, membrane blebbing and cell shrinkage. 9, 10 Apoptosis is initiated by the activation of either caspase-8 or caspase-9, leading to the activation of executioner caspases such as caspase-3 -6 and -7. Most chemotherapeutic agents, including microtubule-active drugs, can induce apoptosis; novel experimental therapeutics such as flavopiridol, an agent with ambiguous mechanism of action, and PS-341, a proteasome inhibitor, are especially potent inducers of apoptosis. [11] [12] [13] [14] [15] [16] However, chemotherapeutic agents also induce apoptosis in normal cells, limiting therapy of cancer. Development of multidrug resistance (MDR) further limits chemotherapy in cancer. 17 Drug transporters, such as multidrug resistance-associated protein (MRP) and P-glycoprotein (Pgp), reduce intracellular drug accumulation due to an active drug efflux from a cell. 18, 19 Pgp confers resistance not only to anticancer drugs but also to a wide spectrum of molecular therapeutics including HIV-protease inhibitors. 20 Linear and cyclic peptides comprise a diverse class of Pgp substrates: from small tripeptides to cyclic dodecapeptides such as cyclosporin A. 19 Peptide protease inhibitors, such as acetyl-leucylleucyl-norleucinal (ALLN), are substrates for Pgp. 21 
Materials and methods

Cell lines and reagents
HL60 and Jurkat, human leukemia cell lines, were obtained from American Type Culture Collection (Manassas, VA, USA). HL60/MRP or HL60/ADR cells, multidrug-resistant due to MRP clone of HL60 cells, were described previously.
22
HL60/Pgp or HL60/TX, multidrug-resistant due to MDR1 clone of HL-60 cells, was obtained from Dr Bhalla and described previously. 22, 23 Paclitaxel (Taxol), was a Bristol-Myers product. Epothilones A and B were provided by Dr F Lee (BristolMyers Squibb, Princeton, NJ, USA). Flavopiridol was obtained from the Development Therapeutics Program, NCI. Flavopiridol was prepared as 10 mM stock solution in DMSO. Adriamycin was obtained from Sigma (St Louis, MO, USA) and dissolved in DMSO as a 2 mg/ml stock solution. The proteasome inhibitor PS341 was a kind gift from Dr Peter Elliott 
Immunoblot analysis
Cells were lysed and soluble proteins were harvested in TNES buffer (50 mM TrisHCl pH 7.5, 100 mM NaCl, 2 mM EDTA, 1 mM sodium orthovanadate, 1% (v/v) NP40) containing protease inhibitors (20 g/ml aprotinin, 20 g/ml leupeptin, 1 mM PMSF). Proteins were resolved with 4-20% SDS-PAGE as previously described. 22 Immunoblotting for PARP and phos-pho-Rb were performed using mouse monoclonal anti-human phospho-Rb antibodies (Ser 612, Oncogene) and rabbit polyclonal anti-human PARP (Upstate Biotechnology, Lake Placid, NY, USA).
MTT assay
Fifteen thousand cells were plated in 96-well flat bottom plates and then exposed to the pharmacological agents. At the indicated time (1-2 days), 20 l of 5 mg/ml MTT solution in PBS was added to each well for 2 h. After removal of the medium, 170 l of DMSO was added to each well to dissolve the formazan crystals. The absorbance at 540 nm was determined using a Biokinetics plate reader (Bio-Tek Instruments, Winooski, VT, USA). Triplicate wells were assayed for each condition and standard deviations were determined. 
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Number of dead and live cells
Cells were plated in 24-well plates in 1 ml of medium, or in 96-well plates in 0.2 ml, and were treated with the drugs. After the indicated time, cells were counted in triplicate on a Coulter Z1 cell counter (Hialeah, FL, USA). In addition, cells were incubated with trypan blue and the numbers of blue (dead) cells and transparent (live) cells were counted in a hemocytometer.
Cell cycle analysis
Cells were washed with PBS and resuspended in 75% ethanol in PBS and kept at 4°C for at least 30 min. Prior to analysis, cells were washed again with PBS and resuspended and incubated for 30 min in propidium iodide staining solution containing 0.05 mg/ml propidium iodide (Sigma), 1 mM EDTA, 0.1% Triton-X-100 and 1 mg/ml RNAse A in PBS. The suspension was then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan (Franklin Lakes, NJ, USA).
Nuclear fragmentation assay
Cells were incubated with flavopiridol with or without caspase, washed with PBS, pelleted on to glass slides in a cyto- MTT assay was performed after 48 h as described in Methods. Results were calculated as percent of control (1, 5, 9) and represent mean ± s.d. Arrows show protection in normal HL60 but not in drug-resistant cells. (b) The cells were treated as described in panel a. After 16 h, cells were lysed and immunoblot for PARP was performed as described in Methods. Arrows show the abrogation of PARP cleavage in normal HL60 but not in drug-resistant cells.
Leukemia
Figure 3
Effects of DEVD-fmk on flavopiridol-induced nuclear fragmentation in parental and multidrug-resistant cells. HL60 cells and HL/Pgp were treated with 300 nM flavopiridol alone or in combination with 20 M DEVD-fmk. After 16 h, DAPI staining was performed as described in Methods.
centrifuge, fixed with 90% ethanol and 10% glacial acid and stained with DAPI as described previously. 15 Nuclei were visualized under UV microscopy. 
Results
Choosing chemotherapeutic agents and caspase inhibitors
A chemotherapeutic agent of choice must be active in drugresistant cells. It has been shown that MRP1-expressing cells were not resistant to paclitaxel (PTX); and both MRP1 and PgP-expressing cells were not resistant to epothilone B (EpoB). 22, 24, 25 As shown in Figure 1a , Pgp-and MRP1-expressing HL-60 cells were normally sensitive to flavopiridol with the maximal cytotoxic effect at 300 nM. Since this dose of flavopiridol kills most of the cells by 36 h (Figure 1a) , it was chosen for further experiments.
I investigated the effects of Z-VAD-fmk on the cytotoxicity of chemotherapeutic agents (Figure 1a-c) . In parental HL60 cells, Z-VAD-fmk partially abrogated the cytotoxicity of PTX or Epo B and potently abrogated the cytotoxicity of flavopiridol (Figure 1a ). This caspase inhibitor also protected HL/MRP cells (Figure 1b (Figure 4a ). In contrast, Z-DEVD-fmk was selective for HL60 (Figure 4b ). It has been demonstrated that caspase-8 is also involved in flavopiridol-induced apoptosis. 26 Z-VEID-FMK, an inhibitor of caspase-6, and Z-IETD-FMK an inhibitor of caspase-8, protected normal but not multidrugresistant cells (Figure 4c, d) . Four other caspase inhibitors tested, Z-VDVAD-FMK (caspase-2), Z-YVAD-FMK (caspase-1), Z-WEHD-FMK (caspase-5) and Z-LEHD-FMK (caspase-9), were only marginally protective (data not shown).
Reversal of resistance restores protection by DEVDfmk
In contrast to a classical approach to increase the cytotoxicity by increasing intracellular concentration of anticancer drug, the approach described here is not intended either to increase the cytotoxicity of chemotherapeutic agents or to increase their intracellular concentration. 
Caspase inhibitors do not affect growth arrest caused by flavopiridol
Caspase inhibitors abrogated flavopiridol-induced apoptosis in parental HL60 cells. However, as shown in Figure 6 , the caspase inhibitor did not abrogate the cytostatic effects caused by low doses of flavopiridol. Flavopiridol arrested cells in G1 and G2 phases of the cell cycle (Figure 6b ) and caused apoptosis, as evidenced by a sub-G1 peak (Figure 6b, arrow) . The caspase inhibitor did not affect the ability of flavopiridol to arrest cell growth, but prevented the appearance of the sub-G1 apoptotic cells (Figure 6b ). The cytostatic effects cannot be blocked by caspase inhibitors. Thus, although caspase inhibitors prevented PARP cleavage, they do not prevent Rb dephosphorylation (Figure 6c ). As shown in Figure 6d , HL60 cells that were exposed to the combination of flavopiridol plus caspase inhibitor for 36 h were still alive, whereas cells exposed to flavopiridol alone were dead. Taking into account the cytostatic effect, this strategy favors a pulse treatment with chemotherapeutic drugs rather than a prolonged treatment.
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Discussion
Multidrug resistance, including expression of drug efflux pumps such as Pgp and MRP, is one of the obstacles in cancer therapy. However, drug resistance can be exploited for therapeutic advantages. 22 Molecules are pumped out according to their structures, not to their functions. Therefore, MDR may confer resistance not only to cytotoxic but also to cytoprotective agents. Pgp-expressing multidrug-resistant cells can pump out a wide variety of small cell permeable peptides. 21 Small peptide inhibitors of caspases inhibit apoptosis caused by most chemotherapeutic agents. In animal models, caspase inhibitors abrogate apoptosis caused by experimental conditions. For example, caspase inhibitor abrogated the apoptotic response in ischemic liver and fully protected rats from death. 27 In rats, Ac-VAD, z-DEVD-fmk, and B-D-fmk protected auditory sensory cells from cisplatin-damage induced loss. 28 Z-VAD-fmk prevented Fas-induced damage of mouse liver 29 and protected from lethal apoptosis LPSinduced acute lung injury in mice. 30 Inhibitors of caspases are under development for treatment of several conditions including stroke, meningitis, and sepsis. [31] [32] [33] In contrast, inhibitors of caspases are seemingly contraindicated in cancer therapy, since induction of apoptosis but not inhibition of apoptosis is the goal of cancer therapy.
The dilemma of protection of normal cells without inhibition of apoptosis in cancer cells can be solved in multidrugresistant tumors. Since the proposed approach does not rely on either overcoming or reversing the resistance to chemotherapy, MDR cells should still be sensitive to at least one chemotherapeutic agent. Both MRP-and Pgp-expressing HL60 cells were still sensitive to flavopiridol (data herein), PS-341, and epothilone B. 15, 22, 24, 25 In parental cells, caspase inhibitors B-D-fmk, Z-VAD-fmk, DEVD-fmk and Z-VEID-fmk abrogated drug-induced apoptosis. Caspase inhibitors prevented PARP cleavage, nuclear fragmentation, and sub-G1 peak on flow cytometry, and dramatically increased survival of normal cells. Caspase inhibitors did not abrogate druginduced apoptosis in multidrug-resistant cells. Moreover, the reversal agent PSC 833 rendered Pgp-cells a DEVD-mediated cytoprotection, 'paradoxically' increasing their resistance.
The ability to discriminate drug-resistant and normal cells varied among caspase inhibitors. Thus, B-D-fmk was the least selective. This low molecular weight (mw 263.3) peptide protected not only normal cells but also MRP cells and partially protected Pgp cells. The caspase inhibitor Z-VAD-fmk did not rescue the Pgp-expressing cells but protected the MRPexpressing cells. Finally, DEVD-fmk and Z-VEID did not protect either MRP-or MDR-1-expressing cells. Currently, caspase inhibitors are not intentionally designed to be substrates of drug transporters. Future development of caspase inhibitors as substrates of drug transporters may be needed. Nevertheless, a combination of DEVD-fmk with flavopiridol is an example of a desirable combination. One hundred nM flavopiridol causes apoptosis, and these doses were achieved in clinical trials. 34, 35 As with other chemotherapeutics, sideeffects limit therapy by flavopiridol. 36 Clinical application of caspase inhibitors may diminish toxic side-effects of chemotherapy in patients with multidrug-resistant tumors.
Previously, I demonstrated that low cytostatic doses of doxorubicin or etoposide, both substrates of Pgp and MRP, protected normal cells but not multidrug-resistant cells from the cytotoxicity caused by microtubule-active drugs. 22 However, overdosing of cytostatic drugs is toxic for cells, thereby narrowing the protection index. In comparison with doxorubicin or etoposide, caspase inhibitors are not intrinsically toxic. Also, low doses of doxorubicin can protect cells only from the cytotoxicity of cycle-dependent drugs. Given their mechanism of cytoprotection, caspase inhibitors may prevent the toxicity of any drug that causes apoptosis.
Two limitations can be envisioned. 
